

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5967943

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD		12/19/2019
RECEIVING PARTY DATA		
Name:	MONASH UNIVERSITY	
Street Address:	WELLINGTON ROAD	
City:	CLAYTON, VICTORIA	
State/Country:	AUSTRALIA	
Postal Code:	3800	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	15521414	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2693377834	
Email:	patent@honigman.com	
Correspondent Name:	KELLY T. MURPHY	
Address Line 1:	650 TRADE CENTRE WAY	
Address Line 2:	SUITE 200	
Address Line 4:	KALAMAZOO, MICHIGAN 49002-0402	
ATTORNEY DOCKET NUMBER:	232435-460776	
NAME OF SUBMITTER:	KELLY T. MURPHY	
SIGNATURE:	/Kelly T. Murphy/	
DATE SIGNED:	02/18/2020	
Total Attachments: 6		
source=GSK_to_Monash_Assignment#page1.tif		
source=GSK_to_Monash_Assignment#page2.tif		
source=GSK_to_Monash_Assignment#page3.tif		
source=GSK_to_Monash_Assignment#page4.tif		
source=GSK_to_Monash_Assignment#page5.tif		

DATED

19 December 2014

GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

and

MONASH UNIVERSITY

PATENT ASSIGNMENT

THIS ASSIGNMENT is made the ^{19th} day of December, 2019 ("Effective Date")

BETWEEN:

- (1) **GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED**, a company incorporated in England and Wales (registered number 00305979) whose registered office is at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (the "GSK or Assignor"); and
- (2) **MONASH UNIVERSITY** acting through the Monash Institute Pharmaceutical Science in the Faculty of Pharmacy & Pharmaceutical Sciences ("Monash") having offices at Royal Parade, Melbourne, Victoria, Australia ("Assignee").

WHEREAS:

- (A) This Assignment is entered into pursuant to a Termination Agreement dated ^{19 December} 2019 between GSK and the Assignee ("Termination Agreement").
- (B) Assignor has agreed to assign to the Assignee all right, title and interest in and to its rights in the patent registrations (and patent applications) for which it is named as proprietor (or applicant, as applicable) in Schedule 1 to this Assignment (the "Patents").

NOW IT IS HEREBY AGREED AS FOLLOWS:

1. DEFINITIONS AND INTERPRETATION

Capitalised terms used, but not otherwise defined, in this Assignment shall have the meaning given to them in the Termination Agreement.

2. ASSIGNMENT

- 2.1 As of the Effective Date, and pursuant to the Termination Agreement and in consideration for the mutual obligations thereunder, Assignor hereby assigns to Assignee all of Assignor's right, title and interest in and to the Patents including all rights, privileges and advantages thereto, for the full term of the Patents.

3. GOVERNING LAW AND JURISDICTION

- 3.1 This Assignment shall be governed by and construed in accordance with English law. Any matter, claim or dispute arising out of or in connection with this Assignment, whether contractual or non-contractual, is to be governed by and determined in accordance with English law.
- 3.2 The courts of England are to have jurisdiction to settle any dispute, whether contractual or non-contractual, arising out of or in connection with this Assignment. Any proceedings shall be brought only in the courts of England.

- 3.3 Each party waives (and agrees not to raise) any objection, on the ground of forum non conveniens or on any other ground, to the taking of proceedings in the courts of England. Each party also agrees that a judgment against it in proceedings brought in England shall be conclusive and binding upon it and may be enforced in any other jurisdiction. Each party irrevocably submits and agrees to submit to the jurisdiction of the English courts.

IN WITNESS WHEREOF this Assignment has been executed by or on behalf of the parties on the date first above written.

GLAXOSMITHKLINE INTELLECTUAL
PROPERTY DEVELOPMENT LIMITED

MONASH UNIVERSITY

By: _____

Name: _____

Date: _____

By: 

Name: Professor Marc Panlary

Date: 18/12/2017

PATENT

REEL: 051845 FRAME: 0129

IN WITNESS WHEREOF this Assignment has been executed by or on behalf of the parties on the date first above written.

GLAXOSMITHKLINE INTELLECTUAL
PROPERTY DEVELOPMENT LIMITED

MONASH UNIVERSITY

By: _____

Name: _____

Date: _____

Authorised Signatory
For and on behalf of
Edinburgh Pharmaceutical Industries Ltd
Corporate Director

Authorised Signatory
For and on behalf of
Glaxo Group Limited
Corporate Director

By: _____

Date: _____

Schedule 1

PATENTS

WO2016/067252

Country	Owner	Patent application Number	Grant Date	Expiration Date
PCT	GSK	WO2016/067252	inactive	n/a
Australia	GSK	2015338717	4 Apr 2019	29 Oct 2035
Brazil	GSK	BR1120170089238	pending	29 Oct 2035
Canada	GSK	2965759	pending	29 Oct 2035
China	GSK	201580058965.9	pending	29 Oct 2035
European Patent Convention	GSK	15813099.7	pending	29 Oct 2035
India	GSK	201717014064	pending	29 Oct 2035
Indonesia	GSK	P00201702705	pending	29 Oct 2035
Mexico	GSK	MX/A/2017/005892	pending	29 Oct 2035
South Africa	GSK	2017/02717	pending	29 Oct 2035
US	GSK	15/521414	pending	29 Oct 2035
US provisional	GSK	62/073821	inactive	n/a
US provisional	GSK	62/189252	inactive	n/a

PATENT